Status:
AVAILABLE
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
Lead Sponsor:
Eisai Inc.
Conditions:
Epilepsies, Myoclonic
Drug Resistant Epilepsy
Eligibility:
All Genders
2+ years
Brief Summary
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
Eligibility Criteria
Inclusion
- Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North American Consensus Panel, 2017) or other refractory epilepsy (per the judgment of the treating physician)
- Male or female, age at least 2 years at the time of informed consent
- Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304
- Has a clinical benefit from lorcaserin in the opinion of the treating physician
Exclusion
- None
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04457687
Last Update
January 30 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
David Geffen School of Medicine, UCLA Mattel Children's Hospital
Los Angeles, California, United States, 90095
3
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
4
Pena
Avon, Connecticut, United States, 06001